The Bermuda Triangle may not be the biggest mystery of the Atlantic. In a new study published in the journal Geophysical Research Letters, scientists believe they have discovered the reason why ...

Structure Therapeutics’ stock soared toward an 18-month high in early Monday trading, after mid-stage data for its oral daily GLP-1 receptor appeared comparable to that of one of Eli Lilly’s ...

Dec 8 (Reuters) - Structure Therapeutics (GPCR.O), opens new tab said on Monday its obesity pill showed weight loss of up to 11.3% after 36 weeks of treatment in a mid-stage study, driving the company ...

Amid an outpouring of obesity data Monday, Wave Life Sciences and Structure Therapeutics were among the biotechs jockeying to set their weight loss assets apart in an increasingly crowded field as ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Structure Therapeutics ...

OpenAI announced Tuesday morning that it had completed a tumultuous corporate restructuring effort, simplifying a complex ownership web into a controlling nonprofit entity and a reimagined for-profit ...

Structure Therapeutics Inc. is a clinical-stage biotech focused on oral GLP-1 drugs for obesity, targeting a rapidly growing sector in pharma market. GPCR's valuation appears attractive given a $1B ...

Strong financial position with cash, cash equivalents and short-term investments of $786.5 million as of June 30, 2025 expected to fund projected operations and key clinical milestones through at ...

Choosing a business structure may not be the most glamorous part of starting a business. In fact, it can actually feel a little daunting. But the business structure you choose can affect how you pay ...

James is a published author with multiple pop-history and science books to his name. He specializes in history, space, strange science, and anything out of the ordinary.View full profile James is a ...

I maintain a Hold rating on Structure Therapeutics due to competitive pressures and lingering doubts about aleniglipron’s efficacy and data integrity. Aleniglipron’s tolerability could be a ...

Happy Friday! You may have noticed there was no Pentagon Rundown last week. That’s because I was at the Modern Day Marine exhibition in Washington, D.C., writing about various topics, including the ...